Please login to the form below
Merck KGaA
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Merck KGaA's 2013 sales performance.
FDA clears Novartis’ Tabrecta for METex14 lung cancer
Rival Merck KGaA’s Tepmetko not yet approved by FDA. Novartis has secured accelerated approval in the US for Tabrecta, the first targeted therapy for advanced non-small cell lung cancer ... The oral, twice-daily drug has been approved by the FDA ahead
Lundbeck drops Parkinson’s drug acquired in €905m deal
Lundbeck paid 100m upfront for Merck Serono spinout Pexton and foliglurax two years ago, with another 805m tied to development and sales milestones.
Merck gets first approval for MET inhibitor tepotinib in Japan
First worldwide approval for MET inhibitor. Japan’s medicines regulator has approved Merck KGaA’s oral MET inhibitor tepotinib for non-small cell lung cancer with MET exon 14 (METex14) mutations, ... Merck has been awarded breakthrough status from
Staying ahead in the era of precision medicine
to our advisory board Co-Chair Dr Zhen Su, Head of Merck KGaA’s global oncology franchise.
Trump calls on FDA to cut ‘red tape’ as coronavirus drug trials gather pace
Finally, Merck KGaA has donated a supply of its interferon beta-1a product Rebif – approved for multiple sclerosis - to France’s INSERM research organisation following a request for use in a
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
COVID-19 Updates and Daily News
Featured jobs
- After the watershed: the dos and don’ts of digital KPIs in a post-pandemic world
- Roche says antibody test for COVID-19 should be ready in May
- Regeneron says antibody for COVID-19 could be ready this year
- Moderna’s coronavirus vaccine hits first objectives
- UK’s new COVID-19 trial initiative fast-tracks BerGenBio’s bemcentinib
- Novartis to test canakinumab for COVID-19, as IL-6 trial disappoints
- AZ secures capacity for one billion coronavirus vaccine doses
- EMA starts review of MorphoSys’ tafasitamab for lymphoma
- Gilead, Galapagos dip on mixed ulcerative colitis data
- Roche makes protein degradation play with $135m Vividion deal
- Octapharma cleared to start phase 3 trial of Octagam in COVID-19
- UK government expands coronavirus testing criteria
PMHub
McCann Health Medical Communications
We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....
Latest intelligence
- OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa
- Ben Speller shares his thoughts on the value of disease specific congresses...
- OPEN Health use PR to support clinical trial recruitment
- International Clinical Trials Day finds clinical research in the spotlight like never before, with any news coming from the many studies into potential vaccines and treatments for SARS-CoV-2...
- Covid-19: what could it mean for the diabetic population?
- Steve How and Oli Hudson, of Wilmington Healthcare, assess the scale of the diabetes crisis and how coronavirus might impact on it...
Quick links
Infographics
